Search

Displaying results 1871 - 1880 of 5263 in total
  1. Drug

    Procyclidine

    go.drugbank.com/drugs/DB00387
    ApprovedInvestigational

    A muscarinic antagonist that crosses the blood-brain barrier and is used in the treatment of drug-induced extrapyramidal disorders and in parkinsonism.

  2. Drug

    Nalidixic acid

    go.drugbank.com/drugs/DB00779
    ApprovedWithdrawn

    Nalidixic acid is a synthetic 1,8-naphthyridine antimicrobial agent with a limited bacteriocidal spectrum. It is an inhibitor of the A subunit of bacterial DNA gyrase.

  3. Drug

    Linerixibat

    go.drugbank.com/drugs/DB11729
    ApprovedInvestigational

    [A275481, A275482] On March 19, 2026, linerixibat was approved by the FDA for the treatment of cholestatic pruritus in patients with primary biliary cholangitis (PBC). … [A275482, L56120] Linerixibat functions by interrupting the enterohepatic circulation of these bile acids, thereby reducing their systemic concentration.[A275482]

  4. Drug

    Enalaprilat

    go.drugbank.com/drugs/DB09477
    ApprovedInvestigational

    Used in the treatment of hypertension, enalapril is an ACE inhibitor that prevents Angiotensin Converting Enzyme (ACE) from transforming angiotensin I into angiotensin II. … Removal of the problematic thiol group from captopril resulted in enalaprilat, which was then modified further with an ester to create the orally available pro-drug enalapril.

  5. Drug

    Abrocitinib

    go.drugbank.com/drugs/DB14973
    ApprovedInvestigational

    Atopic dermatitis is characterized by epidermal hyperplasia, skin barrier dysfunction, and the aberrant activation of immune cells. … [L39779] Health Canada also approved the use of abrocitinib in pediatric patients 12 years and older.[L42395]

  6. Drug

    Protamine sulfate

    go.drugbank.com/drugs/DB09141
    ApprovedInvestigational

    Despite the relative importance of protamine sulfate's medical indication, the medication can notoriously cause a variety of potentially rare but genuinely severe adverse effects that include systemic

  7. Drug

    Catridecacog

    go.drugbank.com/drugs/DB09310
    Approved

    When activated by thrombin at the site of injury, the FXIII A2B2 pro-enzyme is cleaved resulting in activation of the catalytic A-subunit and dissociation from its carrier B-subunit. … from pooled human plasma.

  8. Drug

    Ramucirumab

    go.drugbank.com/drugs/DB05578
    ApprovedInvestigational

    In contrast to other agents directed against VEGFR-2, ramucirumab binds a specific epitope on the extracellular domain of VEGFR-2, thereby blocking all VEGF ligands from binding to it. … By binding to VEGFR2, ramucirumab prevents binding of its ligands (VEGF-A, VEGF-C, and VEGF-D), thereby preventing VEGF-stimulated receptor phosphorylation and downstream ligand-induced proliferation,

  9. Drug

    Arachidonic Acid

    go.drugbank.com/drugs/DB04557
    ApprovedInvestigationalWithdrawn

    It is formed by the synthesis from dietary linoleic acid and is a precursor in the biosynthesis of prostaglandins, thromboxanes, and leukotrienes. [PubChem]

  10. Drug

    Neostigmine

    go.drugbank.com/drugs/DB01400
    ApprovedInvestigationalVet approved

    A cholinesterase inhibitor used in the treatment of myasthenia gravis and to reverse the effects of muscle relaxants such as gallamine and tubocurarine. Neostigmine, unlike physostigmine, does not cross the blood-brain barrier.

    Synonyms: 3-Trimethylammoniumphenyl N,N-dimethylcarbamate